CN1613463A - 一种外用治疗关节疼痛的中药组合物贴膏 - Google Patents
一种外用治疗关节疼痛的中药组合物贴膏 Download PDFInfo
- Publication number
- CN1613463A CN1613463A CN 200310103547 CN200310103547A CN1613463A CN 1613463 A CN1613463 A CN 1613463A CN 200310103547 CN200310103547 CN 200310103547 CN 200310103547 A CN200310103547 A CN 200310103547A CN 1613463 A CN1613463 A CN 1613463A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- plaster
- specific water
- composition plaster
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000006820 Arthralgia Diseases 0.000 title claims description 15
- 239000003814 drug Substances 0.000 claims abstract description 103
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims abstract description 64
- 239000011505 plaster Substances 0.000 claims abstract description 51
- 230000000694 effects Effects 0.000 claims abstract description 43
- 229960001047 methyl salicylate Drugs 0.000 claims abstract description 32
- 239000000284 extract Substances 0.000 claims abstract description 15
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims abstract description 14
- 239000012530 fluid Substances 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 22
- 239000000758 substrate Substances 0.000 claims description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 13
- 239000010238 camphora Substances 0.000 claims description 13
- 229940025250 camphora Drugs 0.000 claims description 13
- 210000000582 semen Anatomy 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- -1 polyethylene Polymers 0.000 claims description 10
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 8
- 230000000857 drug effect Effects 0.000 claims description 8
- 239000004744 fabric Substances 0.000 claims description 8
- 239000000945 filler Substances 0.000 claims description 8
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 7
- 239000005995 Aluminium silicate Substances 0.000 claims description 7
- 235000012211 aluminium silicate Nutrition 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000003431 cross linking reagent Substances 0.000 claims description 7
- 229960002358 iodine Drugs 0.000 claims description 7
- 239000011630 iodine Substances 0.000 claims description 7
- 229910052740 iodine Inorganic materials 0.000 claims description 7
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 7
- 239000003961 penetration enhancing agent Substances 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 239000000080 wetting agent Substances 0.000 claims description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
- DKNPRRRKHAEUMW-UHFFFAOYSA-N Iodine aqueous Chemical compound [K+].I[I-]I DKNPRRRKHAEUMW-UHFFFAOYSA-N 0.000 claims description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
- 239000000600 sorbitol Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 235000010489 acacia gum Nutrition 0.000 claims description 5
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 5
- 239000004927 clay Substances 0.000 claims description 5
- 229920000742 Cotton Polymers 0.000 claims description 4
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 4
- 229910021502 aluminium hydroxide Inorganic materials 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 239000004743 Polypropylene Substances 0.000 claims description 3
- 239000004745 nonwoven fabric Substances 0.000 claims description 3
- 229920000058 polyacrylate Polymers 0.000 claims description 3
- 229920001155 polypropylene Polymers 0.000 claims description 3
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229920002545 silicone oil Polymers 0.000 claims description 2
- 239000004408 titanium dioxide Substances 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims 1
- 230000008901 benefit Effects 0.000 abstract description 4
- 239000011159 matrix material Substances 0.000 abstract description 4
- 241001106067 Atropa Species 0.000 abstract 1
- 235000002568 Capsicum frutescens Nutrition 0.000 abstract 1
- 240000008574 Capsicum frutescens Species 0.000 abstract 1
- 241000723346 Cinnamomum camphora Species 0.000 abstract 1
- 229960000846 camphor Drugs 0.000 abstract 1
- 229930008380 camphor Natural products 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 25
- 239000000499 gel Substances 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 15
- 208000002193 Pain Diseases 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 238000000034 method Methods 0.000 description 12
- 230000036407 pain Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 10
- 239000006071 cream Substances 0.000 description 9
- 239000013521 mastic Substances 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 6
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 6
- 230000035515 penetration Effects 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000036783 anaphylactic response Effects 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 229960002504 capsaicin Drugs 0.000 description 3
- 235000017663 capsaicin Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229960004756 ethanol Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 239000013618 particulate matter Substances 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 239000004584 polyacrylic acid Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000001139 anti-pruritic effect Effects 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 238000005266 casting Methods 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003746 feather Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000003507 refrigerant Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- RODXRVNMMDRFIK-UHFFFAOYSA-N scopoletin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2 RODXRVNMMDRFIK-UHFFFAOYSA-N 0.000 description 2
- 238000005204 segregation Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- NFLGAXVYCFJBMK-BDAKNGLRSA-N (-)-menthone Chemical compound CC(C)[C@@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-BDAKNGLRSA-N 0.000 description 1
- RKUNBYITZUJHSG-VFSICIBPSA-N (2S)-3-hydroxy-2-phenylpropanoic acid [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] ester Chemical compound C1([C@@H](CO)C(=O)OC2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-VFSICIBPSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- KKADPXVIOXHVKN-UHFFFAOYSA-N 4-hydroxyphenylpyruvic acid Chemical compound OC(=O)C(=O)CC1=CC=C(O)C=C1 KKADPXVIOXHVKN-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- XEHFSYYAGCUKEN-UHFFFAOYSA-N Dihydroscopoletin Natural products C1CC(=O)OC2=C1C=C(OC)C(O)=C2 XEHFSYYAGCUKEN-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- ATKYNAZQGVYHIB-IXXDHKBRSA-N Norhyoscyamine Natural products C1([C@@H](C(=O)OC2C[C@H]3CC[C@H](N3)C2)CO)=CC=CC=C1 ATKYNAZQGVYHIB-IXXDHKBRSA-N 0.000 description 1
- 101150096185 PAAS gene Proteins 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- ATKYNAZQGVYHIB-IZGVIRRGSA-N [(1r,5s)-8-azabicyclo[3.2.1]octan-3-yl] (2s)-3-hydroxy-2-phenylpropanoate Chemical compound C1([C@H](C(=O)OC2C[C@H]3CC[C@H](N3)C2)CO)=CC=CC=C1 ATKYNAZQGVYHIB-IZGVIRRGSA-N 0.000 description 1
- WPUIZWXOSDVQJU-XYPWUTKMSA-N [(1s,5r)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 2-phenylprop-2-enoate Chemical compound C([C@H]1CC[C@@H](C2)N1C)C2OC(=O)C(=C)C1=CC=CC=C1 WPUIZWXOSDVQJU-XYPWUTKMSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 1
- 229940043234 carbomer-940 Drugs 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000013210 evaluation model Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229950000845 politef Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000001373 regressive effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- FWYIBGHGBOVPNL-UHFFFAOYSA-N scopoletin Natural products COC=1C=C2C=CC(OC2=C(C1)O)=O FWYIBGHGBOVPNL-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- ATKYNAZQGVYHIB-UHFFFAOYSA-N tropaic acid nortropanyl ester Natural products C1C(N2)CCC2CC1OC(=O)C(CO)C1=CC=CC=C1 ATKYNAZQGVYHIB-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
比较例1 | 比较例2 | 比较例3 | 实施例1 | 实施例2 | 实施例3 | 实施例4 | 实施例5 | 实施例6 | 实施例7 | 实施例8 | ||
桃胶 | 6 | 5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | |||||
阿拉伯胶 | 8 | 2 | 3 | |||||||||
明胶 | 4 | |||||||||||
HPMC | 3 | |||||||||||
海藻酸钠 | 15 | |||||||||||
聚丙烯酸钠PAAS | 5 | 8 | 6 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | ||||
聚丙烯酸 | 7 | 4 | ||||||||||
PVA | 0.5 | 3 | 8 | 1 | 3 | 3 | 3 | 3 | 3 | |||
甘油 | 22 | 15 | 12 | 10 | 19 | 8 | 7 | 7 | 7 | 7 | 7 | |
丙二醇 | 8 | 5.5 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | |
山梨醇 | 5 | 3 | 8 | 3 | 5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | ||
PVP | 9 | 3 | 2 | 4 | 6 | 2 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | |
高岭土 | 1.0 | 14 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | |||||
ZnO | 8 | |||||||||||
蒙脱土 | 19 | |||||||||||
CaCO3 | 10 | |||||||||||
膨润土 | 3 | |||||||||||
硅藻土 | 3 | |||||||||||
TiO2 | 3.5 | |||||||||||
SiO2 | 1 | |||||||||||
氢氧化铝 | 1.5 | 1.5 | 3.2 | 2 | 4.3 | 0.1 | 1 | 1 | 1 | 1 | 1 | |
洒石酸 | 0.5 | 0.5 | 1.0 | 1.5 | 2 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | |
药物活性组分 | 辣椒流浸膏 | 0.58 | 0.58 | 0.58 | 0.58 | 0.58 | 0.58 | 0.58 | 1.25 | 1.4 | 0.05 | 0.9 |
颠茄流浸膏 | 0.34 | 0.34 | 0.34 | 0.34 | 0.34 | 0.34 | 0.34 | 0.2 | 0.1 | 0.8 | 0.9 | |
薄荷油 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.2 | 0.02 | 0.2 | 0.005 | |
水杨酸甲酯 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.04 | 0.47 | 0.45 | 0.005 | |
樟脑 | 0.57 | 0.57 | 0.57 | 0.57 | 0.57 | 0.57 | 0.57 | 0.15 | 0.001 | 0.2 | 0.005 | |
碘 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.05 | 0.001 | 0.1 | 0.005 | |
碘化钾 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.001 | 0.1 | 0.005 | |
盐酸苯海拉明 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.05 | 0.001 | 0.1 | 0.005 | |
吐温80 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.7 | 3.5 | 0.5 | 0.1 | |
水 | 75 | 45 | 39 | 57 | 80 | 63 | 40.5 | 40.5 | 40.5 | 40.5 | 40.5 | |
初粘性 | 17 | 18 | 22 | 26 | 25 | 26 | 24 | 19 | 21 | 24 | 23 | |
表面光洁度 | 优 | 优 | 优 | 优 | 优 | 优 | 优 | 优 | 优 | 优 | 优 | |
内聚强度 | 良 | 优 | 优 | 优 | 优 | 优 | 优 | 优 | 优 | 优 | 优 | |
拔毛现象 | 无 | 无 | 无 | 无 | 无 | 无 | 无 | 无 | 无 | 无 | 无 | |
持粘性 | 优 | 良 | 优 | 优 | 优 | 优 | 优 | 优 | 优 | 优 | 优 | |
抛锚力 | 优 | 优 | 优 | 优 | 优 | 优 | 优 | 优 | 优 | 优 | 优 | |
累积透过量(μg/cm2.天) | 82.3 | 126.9 | 147.2 | 344.8 | 309.2 | 352.1 | 3948 |
起效时间(分钟) | 30 | 60 | 120 | 180 | 240 |
中药组合物贴膏组(%) | 43.28 | 62.69 | 73.13 | 76.12 | 80.60 |
橡胶膏组(%) | 35.38 | 50.77 | 56.92 | 63.08 | 64.62 |
水杨酸甲酯凝胶(%) | 56.81 | 64.25 | 66.27 | 68.09 | 71.22 |
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101035476A CN100482210C (zh) | 2003-11-07 | 2003-11-07 | 一种外用治疗关节疼痛的中药组合物贴膏 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101035476A CN100482210C (zh) | 2003-11-07 | 2003-11-07 | 一种外用治疗关节疼痛的中药组合物贴膏 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1613463A true CN1613463A (zh) | 2005-05-11 |
CN100482210C CN100482210C (zh) | 2009-04-29 |
Family
ID=34756723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2003101035476A Expired - Fee Related CN100482210C (zh) | 2003-11-07 | 2003-11-07 | 一种外用治疗关节疼痛的中药组合物贴膏 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100482210C (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101879250A (zh) * | 2010-06-25 | 2010-11-10 | 安舒贴(天津)外用制剂科技有限公司 | 关节止痛凝胶膏剂及制备方法 |
CN103893727A (zh) * | 2014-03-30 | 2014-07-02 | 禹骏 | 一种止痛活血舒筋贴膏及其制备方法 |
CN105030900A (zh) * | 2015-07-08 | 2015-11-11 | 吴秉民 | 一种治疗风湿类风湿骨性关节炎的外用膏剂及其制备方法和应用 |
CN107296951A (zh) * | 2017-07-28 | 2017-10-27 | 四川利佰生物科技有限公司 | 风湿冷敷贴及其制备方法 |
CN107375528A (zh) * | 2017-08-10 | 2017-11-24 | 杭州仁德医药有限公司 | 一种关节止痛膏及其制备方法 |
CN107432895A (zh) * | 2017-08-17 | 2017-12-05 | 杭州仁德医药有限公司 | 一种用于胜湿止痛的外用贴膏 |
JP2021191766A (ja) * | 2014-06-16 | 2021-12-16 | ユニゲン・インコーポレーテッド | 骨障害、軟骨障害又はその両方の管理又は改善用組成物及び方法 |
CN114652708A (zh) * | 2022-03-07 | 2022-06-24 | 宁波奇致年华医疗科技有限公司 | 一种治疗深部组织疼痛的组合物 |
-
2003
- 2003-11-07 CN CNB2003101035476A patent/CN100482210C/zh not_active Expired - Fee Related
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101879250A (zh) * | 2010-06-25 | 2010-11-10 | 安舒贴(天津)外用制剂科技有限公司 | 关节止痛凝胶膏剂及制备方法 |
CN101879250B (zh) * | 2010-06-25 | 2012-10-31 | 安舒贴(天津)外用制剂科技有限公司 | 关节止痛凝胶膏剂及制备方法 |
CN103893727A (zh) * | 2014-03-30 | 2014-07-02 | 禹骏 | 一种止痛活血舒筋贴膏及其制备方法 |
CN103893727B (zh) * | 2014-03-30 | 2016-08-10 | 禹骏 | 一种止痛活血舒筋贴膏及其制备方法 |
JP2021191766A (ja) * | 2014-06-16 | 2021-12-16 | ユニゲン・インコーポレーテッド | 骨障害、軟骨障害又はその両方の管理又は改善用組成物及び方法 |
CN105030900A (zh) * | 2015-07-08 | 2015-11-11 | 吴秉民 | 一种治疗风湿类风湿骨性关节炎的外用膏剂及其制备方法和应用 |
CN107296951A (zh) * | 2017-07-28 | 2017-10-27 | 四川利佰生物科技有限公司 | 风湿冷敷贴及其制备方法 |
CN107375528A (zh) * | 2017-08-10 | 2017-11-24 | 杭州仁德医药有限公司 | 一种关节止痛膏及其制备方法 |
CN107432895A (zh) * | 2017-08-17 | 2017-12-05 | 杭州仁德医药有限公司 | 一种用于胜湿止痛的外用贴膏 |
CN107432895B (zh) * | 2017-08-17 | 2021-05-25 | 杭州仁德医药有限公司 | 一种用于胜湿止痛的外用贴膏 |
CN114652708A (zh) * | 2022-03-07 | 2022-06-24 | 宁波奇致年华医疗科技有限公司 | 一种治疗深部组织疼痛的组合物 |
CN114652708B (zh) * | 2022-03-07 | 2024-04-26 | 宁波奇致年华医疗科技有限公司 | 一种治疗深部组织疼痛的组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN100482210C (zh) | 2009-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101370487B (zh) | 含有疏水性非甾体抗炎药的经皮制剂 | |
DE69923675T2 (de) | Pharmazeutische trägervorrichtung welche zur verabreichung von wirkstoffen an schleimhautoberflächen geeignet ist | |
EP0341202B1 (de) | Transdermale Monolithsysteme | |
CN102284012B (zh) | 一种含有姜黄素与白芨胶的凝胶贴剂及其制备方法 | |
US10010648B2 (en) | Transdermal delivery system | |
CN1231592A (zh) | 作为渗透促进剂的羟乙酸及其盐的脂肪酸酯 | |
CN105142611A (zh) | 外用组合物及治疗局部病症的方法 | |
JPH04505157A (ja) | 皮膚透過性促進組成物 | |
CN1232389A (zh) | 贴剂 | |
CN1647803A (zh) | 一种外用消炎镇痛的中药组合物贴膏 | |
CN106667970B (zh) | 氟比洛芬巴布剂 | |
CN100482210C (zh) | 一种外用治疗关节疼痛的中药组合物贴膏 | |
CN101961418B (zh) | 一种双控释高剂量低刺激性的辣椒碱复方透皮贴剂 | |
CN102949450B (zh) | 一种治疗局部肌肉和关节疼痛的马钱子生物碱贴剂与制备方法 | |
CN1274342C (zh) | 治疗痛风的中药外用制剂及其制备方法 | |
CN105147642A (zh) | 一种含福莫特罗或其富马酸盐的透皮贴剂 | |
CN106606566A (zh) | 治疗皮肤瘙痒的凝胶贴剂及其制备方法 | |
CN105902483A (zh) | 一种温敏经皮给药材料的制备方法 | |
CN1861059A (zh) | 含辣椒素的亲水性凝胶透皮贴片及其制备方法 | |
CN103432217B (zh) | 一种治疗类风湿性关节炎的外用药物组合物及其制备方法和用途 | |
CN101822652A (zh) | 长春西汀透皮贴剂及其制备方法 | |
CN106361728B (zh) | 经皮吸收制剂及制备经皮吸收制剂的方法 | |
CN106924223A (zh) | 一种美洛昔康贴剂及其制备方法和应用 | |
CN107198762A (zh) | 一种具有治疗乳腺疾病的薄贴及其制备方法 | |
CN100344310C (zh) | 含有生物碱盐的治癣药物及其制备工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder |
Address after: Room 2116, 2 floors, 3 Zhongke Industrial Park, 103 Beiqing Road, Haidian District, Beijing, 100094 Patentee after: Dongfang Kaien Medicine Sci. & Tech. Co., Ltd., Beijing Address before: 100012 Beijing city Chaoyang District huizhongbeili 311 building 3103 room Patentee before: Dongfang Kaien Medicine Sci. & Tech. Co., Ltd., Beijing |
|
CP02 | Change in the address of a patent holder | ||
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Dongfang Kaien Medicine Sci. & Tech. Co., Ltd., Beijing Document name: Notification that Application Deemed not to be Proposed |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: Room 101, unit 2, building MoMA 5, yard 1, anningzhuang West Road, Haidian District, Beijing 100085 Patentee after: BEIJING ORIENTKING PHARMACEUTICAL SCIENCE & TECHNOLOGY Co.,Ltd. Address before: Room 2116, 2 floors, 3 Zhongke Industrial Park, 103 Beiqing Road, Haidian District, Beijing, 100094 Patentee before: BEIJING ORIENTKING PHARMACEUTICAL SCIENCE & TECHNOLOGY Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090429 Termination date: 20201107 |